The European Society for Medical Oncology (ESMO) Congress 2025 took place in Berlin, Germany, marking its 50th anniversary. This first instalment of the Fast Five brings you key insights from leading experts, captured live at the Congress.
In this episode, Barbara Schmalfeldt, University Medical Center Hamburg-Eppendorf, Germany, highlights the major updates in gynaecological cancers presented at ESMO 2025.
- The KEYNOTE-B96 trial and its impact on platinum-resistant ovarian cancer treatment
- Emerging immunotherapy shaping recurrent ovarian cancer management
- Progress and challenges in overcoming gynaecological cancer resistance
- Early data and discussion from the REJOICE-Ovarian01 trial
Stay tuned for more in-depth coverage of the ESMO Congress in the upcoming EMJ Oncology Journal, publishing on 2nd December 2025.
